Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Early treatment for acute promyelocytic leukemia likely improves mother-baby outcomes, with treatment timing guiding safer delivery.

Patient-reported data can predict survival in leukemia, and integrating measuring tools improves care by prioritizing the patient's perspective.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

The combination regimen is so effective because DAC has several mechanisms through which it exerts antileukemic effects.

A Quebec cohort study links gas station proximity to higher VOC exposure and elevated childhood cancer risk, especially acute lymphoblastic leukemia.

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.